216 related articles for article (PubMed ID: 27777099)
1. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
2. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
4. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
5. Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response.
Knoll J; Zelena D; Timar J; Baghy K; Mervai Z; Miklya I
Behav Brain Res; 2020 Jan; 378():112290. PubMed ID: 31610214
[TBL] [Abstract][Full Text] [Related]
6. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
[TBL] [Abstract][Full Text] [Related]
7. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
8. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
9. Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats.
Dalló J; Knoll J
Acta Physiol Hung; 1992; 79(2):125-9. PubMed ID: 1304678
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
[TBL] [Abstract][Full Text] [Related]
11. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
12. Sexual performance and longevity.
Knoll J
Exp Gerontol; 1997; 32(4-5):539-52. PubMed ID: 9315455
[TBL] [Abstract][Full Text] [Related]
13. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
14. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Gaszner P; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of selegiline ((-)deprenyl). New aspects.
Knoll J
Acta Neurol Scand Suppl; 1989; 126():83-91. PubMed ID: 2515725
[TBL] [Abstract][Full Text] [Related]
16. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
18. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Miklya I
Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
[TBL] [Abstract][Full Text] [Related]
19. Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP).
Ernyey AJ; Kassai F; Kozma K; Plangár I; Somfai Z; Miklya I; Gyertyán I
Geroscience; 2024 Feb; 46(1):417-429. PubMed ID: 37306892
[TBL] [Abstract][Full Text] [Related]
20. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Gaszner P; Miklya I
Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
